ANI Pharma (ANIP) Launches Benztropine Mesylate Tablets

October 25, 2016 8:30 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced the launch of Benztropine Mesylate Tablets USP 0.5 mg, 1 mg and 2 mg. The current annual U.S. market for this product is approximately $25 million, according to IMS Health. ANI will immediately launch the product.

Arthur S. Przybyl, ANI's President and CEO stated, "Benztropine is the tenth new commercial product introduction for ANI in 2016. We continue to pursue expansion of our commercial portfolio via internal product development, strategic partnerships, and acquisitions."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Related Entities

Raising Prices

Add Your Comment